Tenon Medical, Inc. 8-K

What Happened
Tenon Medical, Inc. announced it entered into securities purchase agreements on June 29, 2026 and closed a best‑efforts public offering on July 1, 2026, raising aggregate gross proceeds of $4.2 million (before placement agent fees and expenses). The offering included 5,526,315 shares of common stock (and pre‑funded warrants to purchase up to 5,526,316 shares) and common stock purchase warrants to buy up to 13,263,159 shares. Each share (or accompanying pre‑funded warrant) and related common warrant were sold at a combined public offering price of $0.38 per share (pre‑funded warrant exercise price $0.001).

Key Details

• Offering size and structure: $4.2M gross; 5,526,315 common shares (plus pre‑funded warrants for 5,526,316 shares) and common warrants to purchase 13,263,159 shares. Common warrants equal 120% of shares purchased by each investor.
• Warrant terms: Common warrants exercisable immediately at $0.38, expire 5 years after initial exercise; pre‑funded warrants exercisable at $0.001, cashless exercise allowed. Ownership cap: 4.99% (or 9.99% if elected with notice). If a reverse stock split occurs, number of shares issuable under Common Warrants before the split will increase to 16,578,947.
• Placement agent and fees: WallachBeth Capital served as placement agent; cash fee 6.5% of gross proceeds, non‑accountable expense allowance 1%, reimbursement up to $65,000, plus placement agent warrants for 331,579 shares (3% of shares sold) at 120% of the public offering price.
• Restrictions and filings: 30‑day standstill on issuing new equity (with standard exceptions), 3‑month restriction on variable rate transactions, and 60‑day lock‑ups for executives and directors. Offering was made under the company’s Form S‑1 registration statements effective June 29, 2026.

Why It Matters
The financing provides Tenon with near‑term cash to pay down convertible notes and support commercial expansion, clinical studies, R&D, inventory and general corporate needs. However, the issuance of pre‑funded warrants and a large number of common warrants creates potential dilution for existing shareholders if exercised. Investors should note placement agent fees, short lock‑up/standstill periods, and the warrant overhang when assessing near‑term capitalization and dilution risk.